Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Inclusion Criteria: * Healthy male and female older adults greater than or equal to 50 years of age Exclusion Criteria: * Any adult with a history of previous hepatitis B infection * A history of vaccination with any hepatitis B vaccine * Recent (\<72 hours) history of febrile illness (oral temperature =37.8ºC/=100.0ºF) * Known or suspected hypersensitivity to any component of RECOMBIVAX HB™ or ENGERIX-B™ (e.g., aluminum, yeast) * Recent administration (within 3 months prior to first injection with the study vaccine) of hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product * Receipt of licensed inactivated vaccines within 14 days prior to first injection with the study vaccine * Receipt of licensed live virus vaccines within the 30 days prior to injection with the study vaccine * Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine * Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids). Does not include topical and inhaled steroids * Pregnant women, nursing mothers, and women planning to become pregnant within the study period * Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives